JHVEPhoto/iStock Editorial via Getty Images
amgen (NASDAQ:AMGN) shares soared in the premarket on Wednesday after the company dismissed concerns about bone mineral density loss related to its obesity candidate MariTide, leading to a ~7% drop in its stock price in the previous session.